EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + Pembrolizumab

Discussing the EV-103 Cohort K study, which resulted in the FDA approval of Enfortumab Vedotin + Pembrolizumab FDA Approval in the Cisplatin ineligible advanced urothelial carcinoma patients. In discussion with the lead author, Dr. Jonathan Rosenberg - Chief of Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. #immunotherapy #oncology #fda #enfortumab #pembrolizumab #2023 #cancer #oncbrothers Website: http://www.oncbrothers.com/ Twitter:   / oncbrothers   Contact us at [email protected]